Dr. Chandel brings decades of research expertise as the company advances its novel Mitochondria Modifying Agent oncology research program
Penrose TherapeuTx, a pharmaceutical company focused on developing innovative small-molecule therapies for the treatment of advanced cancers, today announced that Navdeep Chandel, Ph.D. has joined the company’s scientific advisory board. Dr. Chandel has more than 20 years of experience in mitochondrial research and has contributed to significant breakthroughs in mitochondrial science, including understanding its role in cancer cells. He joins Penrose as the company is positioned to begin rapidly advancing its novel Mitochondrial Modifying Agent (MMA) research program.
View the full release here: https://www.businesswire.com/news/home/20210310005049/en/
